Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04391166
Other study ID # 200826
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 20, 2020
Est. completion date December 1, 2020

Study information

Verified date March 2021
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prompted by the current COVID-19 pandemic, the American Academy of Ophthalmology has recommended the use of telemedicine to continue ophthalmic care while maintaining patient and provider social distancing. As part of remote examinations, patients may be expected to perform home eye testing for visual acuity and the use of various home visual acuity charts have been proposed to provide clinicians with this vital data. However, the use of home visual acuity exams has not been validated in our patient population. This project aims to determine the efficacy and validity of measuring visual acuity at home with a printed-out ETDRS chart.


Description:

Project Title Validity of Home Visual Acuity Measurements with an ETDRS Chart Project Summary Prompted by the current COVID-19 pandemic, the American Academy of Ophthalmology has recommended the use of telemedicine to continue ophthalmic care while maintaining patient and provider social distancing. As part of remote examinations, patients may be expected to perform home eye testing for visual acuity and the use of various home visual acuity charts have been proposed to provide clinicians with this vital data. However, the use of home visual acuity exams has not been validated in our patient population. This project aims to determine the efficacy and validity of measuring visual acuity at home with a printed-out ETDRS chart. Project Description Rationale: Many ophthalmology visits are being conducted remotely via telehealth. The use of home ETDRS charts is being proposed for patients to report their visual acuity. However, the efficacy and validity of this method in our population should be determined. Objective: Determine the efficacy and validity of measuring visual acuity at home with a printed-out ETDRS chart in the population served by Vanderbilt Eye Institute. Our hypothesis is that measuring visual acuity at home with a printed-out ETDRS is non-inferior to visual acuity measurements by a trained technician in the clinic. Methodology: The study population will include patients scheduled for in-person visits for various subspecialties (Glaucoma, Retina/Uveitis, Pediatrics and Cornea) at Vanderbilt Eye Institute's (VEI) Nashville campus during the period of 4/27/20-5/27/20. Patients will be excluded if they have a last best corrected visual acuity worse than 20/200, have not activated a My Health at Vanderbilt (MHAV) account, or do not speak English. Patients will also need to be between the ages of 18-90 to Approximately one week prior to their appointments, patients will be called to obtain e-consent and provide detailed instructions for measuring best corrected visual acuity at home with the ETDRS chart that is calibrated for 5 feet. Instructions will also be sent via MHAV along with the ETDRS chart and the consent form. Data collected will include age, sex, and primary ophthalmological diagnosis as well as last measured Snellen visual acuity (+/-3months). The department, provider, and date of the in-person appointment will also be collected. Patients will be instructed to complete a home visual acuity check two-four days prior to appointment and send a message through MHAV with the results. Participants will record the smallest full line ( 5 letters) in each eye that they can read. If a message is not received two days prior to the appointment, a research assistant will call the patient back to reconfirm the plan. At the in-person visit, patients will begin their encounter with an ETDRS assessment at VEI, using the ETDRS chart at 20 feet. Again, the full line of 5 letters read will be used for analysis. Patients will receive a survey to be completed in clinic with a 5-point Likert scale to rate the ease of home visual acuity as well as a short response question about barriers to assessment. Data Management and Analysis: Data will be collected from the electronic health record (EHR) and kept in a password-protected deidentified Excel document. Visual acuities will be converted to logMAR for analysis. Ethical Considerations: There are no ethical considerations to report. Barriers to Home Visual acuity testing - Poor/no access to the technical requirements - computer, printer, internet - Do not feel confident of being able to test vision accurately at home - Attempted to test vision at home but was unable to follow instructions completely - Do not want to try it at home, medical procedures should be done in a clinic - Vision too poor to perform these tasks The Home visual acuity test was easy to set up and perform 1. Strongly disagree 2. Disagree 3. Neither agree nor disagree 4. Agree 5. Strongly agree


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date December 1, 2020
Est. primary completion date July 10, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - The study population will include patients scheduled for in-person visits for various subspecialties (Glaucoma, Retina/Uveitis, pediatrics and Cornea) at Vanderbilt Eye Institute's (VEI) Nashville campus during the period of 4/27/20-5/8/20. Exclusion Criteria: - Patients will be excluded if they have a last best corrected visual acuity worse than 20/200. - If they have not activated a My Health at Vanderbilt (MHAV) account - If they do not speak English.

Study Design


Intervention

Other:
Non invasive visual acuity testing
This will be visual acuity at home and visual acuity in clinic both using an ETDRS chart.

Locations

Country Name City State
United States Vanderbilt Eye Institute Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Best Corrected Visual Acuity (BCVA) Per Eye Best Visual Acuity per eye From the time they sign the consent until we take their BCVA in clinic. Approximately 1-2 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT05619432 - Re:Garde Program - Training and Maintaining Visual Perception in Older Adults N/A
Completed NCT03670303 - Trial of an Educational Intervention to Promote Spectacle Use Among Secondary School Children in Islamabad, Pakistan N/A
Completed NCT02896738 - MRI Screening for Auditory Pathway Malformations in Visually Impaired Children
Completed NCT01822717 - Nonvisual Foot Inspection for People With Visual Imapirment N/A
Completed NCT03865134 - Evaluation of Visual - Motor Development in Children With Retinopathy of Prematurity
Active, not recruiting NCT04198350 - Pancreatic Islet Transplantation to the Anterior Chamber of the Eye N/A
Recruiting NCT05220449 - Re-Orchestration of Interregional Oscillatory Activity to Promote Visual Recovery N/A
Completed NCT04190147 - Eye and Growth in Adolescents Born Moderate-to-late Preterm
Completed NCT05135195 - A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training N/A
Recruiting NCT05199363 - Pediatric Patient Experience on a Diagnostic Path N/A
Active, not recruiting NCT03767803 - Collection of Whole Blood Samples for the Evaluation of Preeclampsia (Pre-E) Biomarkers From Pregnant Women
Recruiting NCT03571217 - Shanghai Beixinjing Diabetic Eyes Study
Not yet recruiting NCT03726606 - A Comparison of the Visual Performance of Trifocal Versus Extended Depth of Focus Intraocular Lenses N/A
Completed NCT02259088 - A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients Phase 3
Completed NCT06197607 - Effect of Hand Exercises on Hand Grip Strength and Manual Ability in Children With Visual Impairment N/A
Withdrawn NCT04579653 - Pupillometry and Locus Coeruleus Activation (PuLCA) N/A
Recruiting NCT05844982 - Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy Phase 3
Recruiting NCT02258113 - Measuring of Neuro-visual Functionality With Ocusweep N/A
Completed NCT02607384 - The Baltimore Reading and Eye Disease Study N/A